1. Home
  2. SKE vs MESO Comparison

SKE vs MESO Comparison

Compare SKE & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SKE
  • MESO
  • Stock Information
  • Founded
  • SKE 1979
  • MESO 2004
  • Country
  • SKE Canada
  • MESO Australia
  • Employees
  • SKE N/A
  • MESO N/A
  • Industry
  • SKE Precious Metals
  • MESO Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • SKE Basic Materials
  • MESO Health Care
  • Exchange
  • SKE Nasdaq
  • MESO Nasdaq
  • Market Cap
  • SKE 1.4B
  • MESO 1.3B
  • IPO Year
  • SKE N/A
  • MESO N/A
  • Fundamental
  • Price
  • SKE $15.62
  • MESO $10.98
  • Analyst Decision
  • SKE
  • MESO Buy
  • Analyst Count
  • SKE 0
  • MESO 4
  • Target Price
  • SKE N/A
  • MESO $18.00
  • AVG Volume (30 Days)
  • SKE 444.5K
  • MESO 221.7K
  • Earning Date
  • SKE 08-07-2025
  • MESO 08-28-2025
  • Dividend Yield
  • SKE N/A
  • MESO N/A
  • EPS Growth
  • SKE N/A
  • MESO N/A
  • EPS
  • SKE N/A
  • MESO N/A
  • Revenue
  • SKE N/A
  • MESO $5,670,000.00
  • Revenue This Year
  • SKE N/A
  • MESO $178.09
  • Revenue Next Year
  • SKE N/A
  • MESO $305.06
  • P/E Ratio
  • SKE N/A
  • MESO N/A
  • Revenue Growth
  • SKE N/A
  • MESO N/A
  • 52 Week Low
  • SKE $5.51
  • MESO $5.78
  • 52 Week High
  • SKE $16.41
  • MESO $22.00
  • Technical
  • Relative Strength Index (RSI)
  • SKE 64.53
  • MESO 45.40
  • Support Level
  • SKE $14.94
  • MESO $9.88
  • Resistance Level
  • SKE $16.41
  • MESO $12.50
  • Average True Range (ATR)
  • SKE 0.58
  • MESO 0.36
  • MACD
  • SKE -0.01
  • MESO -0.02
  • Stochastic Oscillator
  • SKE 70.05
  • MESO 30.53

About SKE Skeena Resources Limited

Skeena Resources Ltd is a mining company in development stage focusing on the construction and development of the Eskay Creek project in British Columbia. Eskay Creek is the next global gold development project and represents one of the highest-grade and lowest-cost open-pit precious metals mines, with substantial silver by-product production.

About MESO Mesoblast Limited

Mesoblast Ltd is a biotechnology company. It uses its proprietary technology platform to develop and commercialize allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care and where inflammation plays a central role. The company's product candidates include; Ryoncil (remestemcel-L) for the treatment of steroid refractory acute graft versus host disease as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of cell technology platform for commercialization.

Share on Social Networks: